SUMMARY
- The Librexia program is the milvexian phase 3 program. It will begin with 3 phase 3 clinical trials to evaluate the efficacy and safety of milvexian to prevent thrombosis in patients with a recent acute coronary syndrome (ACS); with atrial fibrillation (AF); or after an acute ischemic stroke (AIS) or high-risk transient ischemic attack (TIA).
- Librexia AF (NCT05757869) is a multicenter, randomized, double-blind, doubledummy, active-controlled, parallel-group, phase 3 study evaluating the efficacy and safety of milvexian 100 mg vs apixaban 5 mg or 2.5 mg in participants aged ≥18 years with AF (N=20,000).1,2
- Librexia ACS (NCT05754957) was a multicenter, randomized, double-blind, placebocontrolled, parallel-group, event-driven, phase 3 study evaluating the efficacy and safety of milvexian 25 mg in participants aged ≥18 years after a recent (within 7 days) ACS (N=16,000).3,4 On November 14, 2025, Johnson & Johnson in collaboration with Bristol Myers Squibb announced the decision to stop the Phase 3 Librexia ACS trial. Please click here for the link to the press release.5
- Librexia STROKE (NCT05702034) is a multicenter, randomized, doubleblind, placebo-controlled, parallel-group, phase 3 trial evaluating the efficacy and safety of milvexian 25 mg for the prevention of recurrent ischemic stroke after an AIS or high-risk TIA (N=15,000).6
- The results of these clinical trials are not yet available.
BRISTOL MYERS SQUIBB AND JOHNSON & JOHNSON COLLABORATION
Milvexian is an oral investigational factor XIa inhibitor being studied for the prevention of major thrombotic conditions in a worldwide collaboration program between Bristol Myers Squibb and Johnson & Johnson. Milvexian is not currently approved for any use.
To read more about how Johnson & Johnson processes personal data, please visit https://innovativemedicine.jnj.com, select your country or region (in the upper right corner), and then click on Privacy Policy.
To read more about how Bristol Myers Squibb processes personal data, please visit https://www.bms.com, select your country (in the upper right corner), and then click on Privacy Policy.
CLINICAL Trials
Librexia AF is an ongoing, multicenter, randomized, double-blind, double-dummy, activecontrolled, parallel-group, phase 3 study evaluating the efficacy and safety of milvexian vs apixaban in participants aged ≥18 years with AF (N=20,000).1,2
Study Design/Methods
- Key inclusion criteria are as follows:
- Participants aged ≥18 years
- Participants who are medically stable and appropriate for chronic antithrombotic treatment
- Participants with AF eligible to receive anticoagulation treatment
- Participants who satisfy 1 or both of the following categories of risk factors:
- One or more of the following risk factors:
- Participants aged ≥75 years
- History of a clinical symptomatic stroke
- Two or more of the following risk factors:
- Age 65-74 years
- Hypertension
- Diabetes mellitus
- Atherosclerotic vascular disease
- Heart failure
- Key exclusion criteria are as follows:
- Hemodynamically significant valve disease or those with valve disease that will potentially require surgical valve replacement during the study.
- Any condition other than AF that requires chronic anticoagulation treatment.
- Participants will be randomized to receive the following on day 1 through end of treatment (EOT):
- Milvexian 100 mg orally twice daily and a placebo capsule that matches apixaban, or
- Placebo that matches milvexian and a capsule containing apixaban 5 mg or 2.5 mg orally twice daily.
- After the EOT visit, participants in both groups may have an option to receive openlabel apixaban at the appropriate dose (5 mg or 2.5 mg twice daily).
- The primary outcome is time to first occurrence of the composite endpoint of stroke and non-central nervous system (CNS) systemic embolism (time frame: up to 4 years)
- The secondary outcomes are as follows:
- Time to first occurrence of International Society of Thrombosis and Hemostasis (ISTH) major bleeding (time frame: up to 4 years)
- Time to first occurrence of the composite of ISTH major and clinically relevant nonmajor (CRNM) bleeding (time frame: up to 4 years)
- Time to first occurrence of the composite endpoint of cardiovascular (CV) death, myocardial infarction (MI), stroke, and non-CNS systemic embolism (time frame: up to 4 years)
- Time to CV death (time frame: up to 4 years)
- Time to first occurrence of the composite endpoint of all-cause death, MI, stroke, and non-CNS systemic embolism (time frame: up to 4 years)
- Time to first occurrence of the composite endpoint of CV death, MI, stroke, acute limb ischemia (ALI) (any unanticipated revascularization or amputation of ischemic limb), and urgent hospitalization for vascular cause of ischemic nature (including deep vein thrombosis [DVT] and pulmonary embolism [PE]) (time frame: up to 4 years)
Results
- This trial is currently ongoing, and the results are not yet available.
Librexia ACS was a multicenter, randomized, double-blind, placebo-controlled, parallel-group, event-driven, phase 3 study evaluating the efficacy and safety of milvexian in participants aged ≥18 years after a recent (within 7 days) ACS (N=16,000).3,4
Study Design/Methods
- Key inclusion criteria were as follows:
- Participants with an index event that met all 3 of the following criteria within 7 days prior to randomization:
- Clinical syndrome consistent with spontaneous cardiac ischemia
- Diagnosis of ACS (i.e., ST-elevation myocardial infarction [STEMI], non-STEMI, or unstable angina [UA])
- Cardiac biomarker elevation (eg, troponin I, troponin T, creatine kinase-MB [CK-MB]) above the upper limit of normal as determined by the local laboratory
- Participants with ≥2 of the following risk factors:
- Age ≥65 years
- Diabetes mellitus
- History of a prior MI (other than index ACS event)
- Multivessel coronary artery disease (CAD)
- History of coronary artery bypass graft (CABG) surgery prior to index ACS event
- History of peripheral artery disease (PAD) or cerebrovascular disease (e.g., carotid atherosclerosis, intracranial artery stenosis)
- Conservative management (i.e., no percutaneous intervention [PCI] or CABG after index ACS event)
- Any 1 or more of the following high-risk angiographic features:
- Total stent length of >30 millimeters
- Thrombotic target lesion
- Bifurcation lesion treated with >1 stent
- Calcified target lesion treated with atherectomy
- Treatment of obstructive left main or proximal left anterior descending artery for index ACS (or clinical diagnosis of an anterior STEMI)
- All female participants of childbearing potential must have had a negative highly sensitive serum beta-human chorionic gonadotropin (hCG) or urine test at screening.
- Female participants must not have been pregnant, breastfeeding, or planning to become pregnant until 4 days (5 half-lives) after the last dose of study intervention.
- Key exclusion criteria were as follows:
- MI secondary to ischemia due to either increased oxygen demand or decreased supply (type 2 MI) or periprocedural MI as the index ACS event
- Planned CABG or staged PCI after randomization
- Any condition that required chronic anticoagulation treatment at the discretion of the investigator and/or local guidelines
- Conditions with a significant increased risk of bleeding (e.g., clinically significant bleeding within the previous 3 months, known bleeding diathesis)
- Participants were randomized to receive the following:
- Milvexian 25 mg orally twice daily + standard-of-care (SoC) antiplatelet therapy (single antiplatelet therapy [SAPT] or dual antiplatelet therapy [DAPT]), or
- Placebo orally twice daily + SoC antiplatelet therapy (SAPT or DAPT)
- The primary outcome was time to first occurrence of major adverse cardiovascular event (MACE) (time frame: up to 3.5 years).
- MACE is a composite of CV death, MI, and ischemic stroke.
- The secondary outcomes were as follows:
- Time to first occurrence of major adverse vascular event (MAVE) (time frame: up to 3.5 years)
- MAVE is a composite of CV death, MI, ischemic stroke, major adverse limb event (MALE), and symptomatic venous thromboembolism (VTE).
- Time to first occurrence of the composite of all-cause mortality (ACM), MI, and ischemic stroke (time frame: up to 3.5 years)
- Time to CV death (time frame: up to 3.5 years)
- Time to ACM (time frame: up to 3.5 years)
- ACM is categorized into CV death, non-CV death, and death due to unknown cause.
Results
- This trial was discontinued, and the results are not yet available.
Librexia STROKE is an ongoing multicenter, randomized, double-blind, placebocontrolled, parallel-group, phase 3 trial evaluating the efficacy and safety of milvexian for the prevention of recurrent ischemic stroke after an AIS or high-risk TIA (N=15,000).6
Study Design/Methods
- Key inclusion criteria are as follows:
- Participants aged ≥40 years
- Participants with ischemic stroke: A neurological deficit attributable to an acute brain infarction and national institute of health stroke score scale [NIHSS] score ≤7 and ≥1 of the following:
- Persistent signs or symptoms of the ischemic event at the time of randomization
- Acute, ischemic brain lesion determined by SoC neuroimaging
- Participant underwent thrombolysis or thrombectomy
- Participants with TIA: Acute onset neurological deficit attributable to focal ischemia of the brain by history or examination, with complete symptom resolution of the deficit and no brain infarction on neuroimaging (eg, computed tomography [CT] scan or magnetic resonance imaging [MRI], performed as part of standard medical practice), and ABCD2 score ≥6
- Participants will be randomized as soon as possible after determining eligibility and ≤48 hours of onset of event.
- Current or planned antiplatelet treatment per international and/or local guidelines.
- If acetylsalicylic acid (ASA) is used, it will be limited to low dose (75 mg to 100 mg/day).
- Loading dose of antiplatelet agents (including ASA) are allowed per SoC.
- A female participant must agree not to be pregnant, breastfeeding, or planning to become pregnant until 4 days (5 half-lives) after the last dose of study intervention.
- Willing and able to adhere to the lifestyle restrictions specified in this protocol
- Key exclusion criteria are as follows:
- Prior history of intracranial hemorrhage except subarachnoid hemorrhage >1 year prior with adequate treatment
- The index stroke or TIA is considered to have a cardio-embolic etiology based on local SoC investigations and for which guidelines recommend anticoagulation.
- The index stroke or TIA considered is to have another known cause, not related to atherothrombotic sources (treatment of acute stroke trial [TOAST] other determined etiology), based on local SoC investigations.
- Increased risk of bleeding, including clinically significant bleeding within the previous 3 months or known bleeding diathesis or known activated partial thromboplastin time (aPTT) prolongation or spinal cord hemorrhage or retinal hemorrhage
- Current active liver disease, eg, acute hepatitis, known cirrhosis, including participants receiving antiviral treatment for hepatitis
- Known allergies, hypersensitivity, or intolerance to milvexian or its excipients
- Participants will be randomized to receive the following:
- Milvexian 25 mg orally twice daily + SoC antiplatelet therapy (SAPT or DAPT), or
- Placebo orally twice daily + SoC antiplatelet therapy (SAPT or DAPT)
- The primary outcome is time to first occurrence of ischemic stroke (time frame: up to a global targeted endpoint date of approximately 41 months).
- The secondary outcomes are as follows:
- Time to first occurrence of any component of the composite of CV death, MI, or ischemic stroke (time frame: up to a global targeted endpoint date of approximately 41 months)
- Time to first occurrence of ischemic stroke (time frame: up to day 90)
- Time to first occurrence of any component of MAVE (time frame: up to global targeted endpoint date of approximately 41 months)
- MAVE is a composite of CV death, MI, ischemic stroke, MALE, symptomatic PE, or DVT.
Results
- This trial is currently ongoing, and the results are not yet available.
Literature Search
A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 04 February 2026.
| 1 | Janssen Research & Development, LLC. A study of milvexian versus apixaban in participants with atrial fibrillation (LIBREXIA-AF). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT05757869 NLM Identifier: NCT05757869. |
| 2 | Jain SS, Mahaffey KW, Pieper KS, et al. Milvexian vs apixaban for stroke prevention in atrial fibrillation: the LIBREXIA atrial fibrillation trial rationale and design. Am Heart J. 2024;277:145-158. |
| 3 | Janssen Research & Development, LLC. A study of milvexian in participants after a recent acute coronary syndrome (LIBREXIA-ACS). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT05754957 NLM Identifier: NCT05754957. |
| 4 | C M Gibson, M C Bahit, R Mehran, et al. Oral factor XIa inhibitor milvexian after a recent acute coronary syndrome: rationale and design of the phase 3 (Librexia ACS). Am Heart J. 2025;285(Epub ahead of print):21-28. |
| 5 | Update on Phase 3 Librexia ACS Trial. Press Release. Bristol Myers Squibb. Available at: https://news.bms.com/news/corporate-financial/2025/Update-on-Phase-3-Librexia-ACS-Trial/default.aspx Bristol Myers Squibb; Accessed Accessed 04 Febraury 2026. |
| 6 | Janssen Research & Development, LLC. A study of milvexian in participants after an acute ischemic stroke or high-risk transient ischemic attack - LIBREXIA-STROKE (LIBREXIA-STROK). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 February 04]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT05702034 NLM Identifier: NCT05702034. |